Lilly secures FDA approval for Ebglyss to treat atopic dermatitis
Eli Lilly's Ebglyss (lebrikizumab-lbkz) receives FDA approval for treating moderate-to-severe atopic dermatitis in individuals aged 12+ weighing at least 40kg, not well controlled by topical therapies. Ebglyss, a targeted IL-13 inhibitor, offers a monthly maintenance injection with initial dosing and potential itch relief, based on ADvocate 1, 2, and ADhere studies. Common side effects include eye and eyelid inflammation, injection site reactions, and shingles. Lilly plans to commercialize Ebglyss in the US and offers support services for patient access.
Reference News
Eli Lilly's Ebglyss (lebrikizumab-lbkz) receives FDA approval for treating moderate-to-severe atopic dermatitis in individuals aged 12+ weighing at least 40kg, not well controlled by topical therapies. Ebglyss, a targeted IL-13 inhibitor, offers a monthly maintenance injection with initial dosing and potential itch relief, based on ADvocate 1, 2, and ADhere studies. Common side effects include eye and eyelid inflammation, injection site reactions, and shingles. Lilly plans to commercialize Ebglyss in the US and offers support services for patient access.